
Novartis finishes the third quarter of the year better than analysts had anticipated, including outperforming in core earnings per share (EPS), reports Bloomberg News.
Consensus estimates collected by Bloomberg News put Novartis's net sales at USD 13bn, but Novartis has marginally exceeded that figure with reported Q3 net sales figures of USD 13.03bn.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app